{"id":469,"date":"2026-04-12T09:34:47","date_gmt":"2026-04-12T09:34:47","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&#038;p=469"},"modified":"2026-08-30T03:53:24","modified_gmt":"2026-08-30T03:53:24","slug":"lucidac-dacomitinib-15-mgx30-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/es\/product\/lucidac-dacomitinib-15-mgx30-tablets\/","title":{"rendered":"LuciDac 15mg"},"content":{"rendered":"<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>HIGHLIGHTS OF PRESCRIBING INFORMATION<\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>These highlights do not include all the information needed to use LuciDac&nbsp;safely and effectively. See full prescribing information for LuciDac.<\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>INDICATIONS AND USAGE<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">LuciDac is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>DOSAGE AND ADMINISTRATION<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">Recommended Dosage: 45 mg orally once daily with or without food.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>DOSAGE FORMS AND STRENGTHS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">Tablets:&nbsp;15&nbsp;mg\u00d730 tablets.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>CONTRAINDICATIONS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">None.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>WARNINGS AND PRECAUTIONS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Interstitial Lung Disease (ILD): Permanently discontinue LuciDac if ILD is confirmed.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Diarrhea: Withhold and reduce the dose of LuciDac based on the severity.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Dermatologic Adverse Reactions: Withhold and reduce the dose of LuciDac based on the severity.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Embryo-Fetal Toxicity: LuciDac can cause fetal harm. Advise females of reproductive potential to use effective contraception.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>ADVERSE REACTIONS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px;\"><span style=\"font-size:16px;color:#595959\">Most common adverse reactions are (incidence &gt;20%) diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>DRUG INTERACTIONS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Proton Pump Inhibitors (PPIs): Avoid use with LuciDac; use locally-acting antacids or H2-receptor antagonist; administer LuciDac at least 6 hours before or 10 hours after H2-receptor antagonist.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;CYP2D6 Substrates: Avoid concomitant use with LuciDac where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities.<\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>USE IN SPECIFIC POPULATIONS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">Lactation: Advise not to breastfeed.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>Storage<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">Store at 20\u2103&nbsp;to 25\u2103&nbsp;(68\u2109&nbsp;to 77\u2109), excursions permitted between 15\u2103&nbsp;and 30\u2103&nbsp;(59\u2109&nbsp;and 86\u2109) [see USP Controlled Room Temperature]. Protect from moisture.&nbsp;<\/span><\/p>\n<p><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LuciDac is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.<\/p>","protected":false},"featured_media":1968,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[19],"product_tag":[],"class_list":["post-469","product","type-product","status-publish","has-post-thumbnail","product_cat-lung-cancer","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/product\/469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/comments?post=469"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/media\/1968"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/media?parent=469"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/product_brand?post=469"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/product_cat?post=469"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/product_tag?post=469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}